Anika Therapeutics Reports on Shareholder Votes
Ticker: ANIK · Form: 8-K · Filed: Jul 11, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Anika Therapeutics held a shareholder vote on July 9th, details filed today.
AI Summary
Anika Therapeutics, Inc. filed an 8-K on July 11, 2024, reporting on matters submitted to a vote of security holders on July 9, 2024. The filing details the company's corporate structure and its principal executive offices located at 32 Wiggins Avenue, Bedford, MA 01730.
Why It Matters
This filing informs shareholders about key decisions made during a vote, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain new financial or operational risks.
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Registrant
- July 9, 2024 (date) — Date of earliest event reported
- July 11, 2024 (date) — Filing date
- 32 Wiggins Avenue, Bedford, MA 01730 (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Anika Therapeutics' security holders on July 9, 2024?
The filing states that matters were submitted to a vote of security holders on July 9, 2024, but does not specify the exact nature of these matters within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 9, 2024.
What is the principal executive office address for Anika Therapeutics, Inc.?
The principal executive office address for Anika Therapeutics, Inc. is 32 Wiggins Avenue, Bedford, MA 01730.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission file number for Anika Therapeutics, Inc.?
The Commission file number for Anika Therapeutics, Inc. is 000-21326.
Filing Stats: 733 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-07-11 16:15:12
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select
Filing Documents
- f8k_071124.htm (8-K) — 28KB
- 0001171843-24-003900.txt ( ) — 196KB
- anik-20240711_lab.xml (EX-101.LAB) — 33KB
- anik-20240711_pre.xml (EX-101.PRE) — 22KB
- anik-20240711.xsd (EX-101.SCH) — 3KB
- f8k_071124_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. Anika Therapeutics, Inc., or the Company, held the 2024 Annual Meeting of Stockholders, or the Annual Meeting, on July 9, 2024. The board of directors of the Company, or the Board, solicited proxies for the Annual Meeting pursuant to the proxy statement, or the Proxy Statement, for the Annual Meeting, which the Company filed with the Securities and Exchange Commission on June 11, 2024. There was no solicitation in opposition to the Board's solicitation. The number of shares of the Company's common stock, $0.01 par value per share, entitled to vote at the Annual Meeting was 14,857,369. A total of 12,387,064 shares of common stock were present in person or by proxy at the Annual Meeting, representing 83.37% of the voting power entitled to vote at the Annual Meeting. Each share of common stock was entitled to one vote with respect to each matter submitted to a vote at the Annual Meeting, and the voting results reported below are final. The matters considered and voted on by the stockholders at the Annual Meeting and the votes of the stockholders were as follows: PROPOSAL 1 Stockholders voted as follows with respect to election of each of the director nominees identified in the Proxy Statement: Nominee For Against Abstain Broker Non-Votes Sheryl L. Conley 10,713,825 415,055 27,858 1,230,326 William R. Jellison 11,092,818 13,085 50,835 1,230,326 Stephen O. Richard 10,205,467 924,213 27,058 1,230,326 As a result of this vote, Ms. Conley and Messrs. Jellison and Richard were elected as Class I directors to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until his or her earlier resignation or removal. PROPOSAL 2 Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Stockholders voted